Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiac Rehabilitation for Patients With Stable Ischemic Heart Disease Without Revascularization　- Rationale and Design of a Single-Arm Pilot Study.
Seki T, Murata M, Takabayashi K, Yanagisawa T, Ogihara M, Kurimoto R, Kida K, Tamita K, Song X, Ozasa N, Taniguchi R, Nishitani-Yokoyama M, Koba S, Murai R, Furukawa Y, Hamasaki M, Kondo H, Hayashi H, Ootakara-Katsume A, Tateishi K, Matoba S, Adachi H, Shiraishi H; START Investigators. Seki T, et al. Among authors: tamita k. Circ Rep. 2023 Feb 25;5(3):90-94. doi: 10.1253/circrep.CR-22-0131. eCollection 2023 Mar 10. Circ Rep. 2023. PMID: 36909138 Free PMC article.
Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation.
Kanaoka K, Onoue K, Terasaki S, Nakano T, Nakai M, Sumita Y, Hatakeyama K, Terasaki F, Kawakami R, Iwanaga Y, Miyamoto Y, Saito Y; Japanese Registry of Fulminant Myocarditis Investigators. Kanaoka K, et al. Circulation. 2022 Nov 8;146(19):1425-1433. doi: 10.1161/CIRCULATIONAHA.121.058869. Epub 2022 Sep 27. Circulation. 2022. PMID: 36164974
Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone: Reports of a Randomised Trial From The Japan Working Group for the Assessment Whether Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study).
Asakura M, Kim J, Asanuma H, Nakama Y, Tsukahara K, Higashino Y, Ishikawa T, Koba S, Tsujimoto M, Himeno H, Maruyama Y, Ookusa T, Yoda S, Suzuki H, Okubo S, Shimizu M, Hashimoto Y, Satake K, Fujino S, Uzui H, Nagai Y, Kohno T, Mizuno S, Nakahama M, Kanaya H, Murohara T, Fukui K, Takase H, Ohte N, Shiono T, Fukunami M, Endo T, Sawada R, Fujii K, Takeuchi M, Ikeda S, Mizuno K, Uematsu M, Matsubara T, Yano S, Takahashi J, Ueda K, Kinoshita Y, Tamita K, Hayashi H, Hamasaki T, Kitakaze M; PPAR investigators. Asakura M, et al. Among authors: tamita k. EClinicalMedicine. 2018 Oct 22;4-5:10-24. doi: 10.1016/j.eclinm.2018.09.006. eCollection 2018 Oct-Nov. EClinicalMedicine. 2018. PMID: 31193597 Free PMC article.
Fulminant fatal cardiotoxicity following cyclophosphamide therapy.
Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, Morioka S, Furukawa Y. Katayama M, et al. Among authors: tamita k. J Cardiol. 2009 Oct;54(2):330-4. doi: 10.1016/j.jjcc.2009.01.006. Epub 2009 Feb 20. J Cardiol. 2009. PMID: 19782276 Free article.
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Asakura M, Kim J, Asanuma H, Hamasaki T, Tsukahara K, Higashino Y, Ishikawa T, Nakama Y, Koba S, Maruyama Y, Tsujimoto M, Himeno H, Ohkusa T, Fujino S, Shimizu M, Endo T, Yoda S, Muroya T, Murohara T, Ohte N, Suzuki H, Kohno T, Fukui K, Shiono T, Takase H, Uzui H, Nagai Y, Hashimoto Y, Ikeda S, Mizuno S, Tamita K, Fujita M, Satake K, Kinoshita Y, Nunohiro T, Sakagami S, Higaki J, Morii I, Sawada R, Hiasa Y, Shigemasa T, Nakahama M, Sata M, Doi O, Ueda T, Yamada T, Yamanouchi T, Yamaguchi H, Morita Y, Hayashi H, Kitakaze M; ABC investigators. Asakura M, et al. Among authors: tamita k. Cardiovasc Drugs Ther. 2017 Aug;31(4):401-411. doi: 10.1007/s10557-017-6740-3. Cardiovasc Drugs Ther. 2017. PMID: 28779371 Clinical Trial.
41 results